CytRx Corporation announced the appointment of Cheryl Cohen, former Chief Commercial Officer of Medivation Inc., to its Board of Directors. Ms. Cohen served as the Chief Commercial Officer of Medivation Inc., from September 2011 to July 2014, where she was responsible for the company's U.S. launch of Xtandi (enzalutamide) for metastatic castration-resistant prostate cancer. Ms. Cohen currently serves as president of CLC Consulting.

Ms. Cohen currently serves on the Board of Directors of Tokai Pharmaceuticals Inc. and Protein Sciences Corporation.